Ming-Lei Zhuo
Overview
Explore the profile of Ming-Lei Zhuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ni J, Huang M, Zhang L, Wu N, Bai C, Chen L, et al.
Thorac Cancer
. 2021 Mar;
12(9):1469-1488.
PMID: 33787090
Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as...
2.
Zhao M, Zhuo M, Zheng X, Su X, Meric-Bernstam F
Oncotarget
. 2019 Dec;
10(65):7014-7015.
PMID: 31857856
[This corrects the article DOI: 10.18632/oncotarget.26530.].
3.
Zhao M, Zhuo M, Zheng X, Su X, Meric-Bernstam F
Oncotarget
. 2019 Feb;
10(1):30-44.
PMID: 30713601
Abnormal FGFR1 alternative splicing is correlated with tumorigenicity and poor prognosis in several tumor types. We sought to determine the roles of FGFR1α and FGFR1β variants in breast cancer. TCGA...
4.
Zhuo M, Bai H, Wang Z, Duan J, An T, Wu M, et al.
Mol Clin Oncol
. 2014 Oct;
2(6):953-959.
PMID: 25279180
Rechallenge chemotherapy with pemetrexed was shown to be efficient in malignant pleural mesothelioma; however, its role in non-small-cell lung cancer (NSCLC) has not been investigated. In this study, we retrospectively...
5.
Wang Y, Zhang H, Bai H, Wang S, Wu M, An T, et al.
Zhonghua Jie He He Hu Xi Za Zhi
. 2013 Jul;
36(3):162-8.
PMID: 23856136
Objective: To identify potential prognosis related clinical and molecular factors in malignant pleural mesothelioma (MPM). Methods: Seventy-nine patients with MPM treated in Beijing Cancer Hospital from June 1996 to May...
6.
Duan J, An T, Wu M, Yang L, Bai H, Wang Z, et al.
Zhonghua Jie He He Hu Xi Za Zhi
. 2012 Aug;
35(5):323-8.
PMID: 22883988
Objective: To investigate the frequency of epidermal growth factor receptor (EGFR) mutations and their correlation with the efficacy of tyrosine kinase inhibitors (EGFR-TKI) in advanced squamous cell lung cancer. Methods:...
7.
Duan J, Wu M, Zhao J, An T, Yang L, Bai H, et al.
Zhonghua Jie He He Hu Xi Za Zhi
. 2012 Mar;
35(2):97-101.
PMID: 22455964
Objective: To evaluate the effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer (NSCLC), and to explore thymidylate synthetase (TS) expression as the predictive and prognostic factor...
8.
Zhuo M, Wu M, Zhao J, Song S, Bai H, Wang S, et al.
Chin Med J (Engl)
. 2012 Feb;
124(21):3510-4.
PMID: 22340169
Background: The genotype of epidermal growth factor receptor (EGFR) is associated with tyrosine kinase inhibitor and effectiveness of therapy, but its role in cytotoxic chemotherapy is still unknown. Previous studies...
9.
Zhuo M, Huang Y, Chen J, Sun L, Yang R, Chen H, et al.
Cardiovasc Res
. 2009 Jun;
84(2):292-9.
PMID: 19541669
Aims: Hypertension is one of the major risk factors for cardiovascular diseases. Endothelial cells (ECs) exert important functions in the regulation of blood pressure. A novel gene, IC53, as an...
10.
Li H, Zhuo M, Wang D, Wang A, Cai H, Sun L, et al.
Circulation
. 2007 Mar;
115(14):1885-94.
PMID: 17389268
Background: A20 was originally characterized as a tumor necrosis factor-inducible gene in human umbilical vein endothelial cells. As an inhibitor of nuclear factor-kappaB signaling, A20 protects against apoptosis, inflammation, and...